Mark Velleca
Chief Executive Officer bij BLACK DIAMOND THERAPEUTICS, INC.
Vermogen: 736 987 $ op 31-03-2024
Profiel
Mark A.
Velleca was the founder of Gilead Connecticut, Inc. (founded in 1999) where he held the title of Senior Vice President from 1999 to 2010.
He is currently the Chairman, President & Chief Executive Officer at Black Diamond Therapeutics, Inc. (since 2021), President, Chief Executive Officer & Director at StrideBio, Inc. (since 2022), Chairman at Turbine Hálózatelemzo Kutatási Fejlesztési Kft.
(since 2021), and Director at IMMvention Therapeutix, Inc. and Yale University.
Dr. Velleca's former positions include Chairman at Turbine Simulated Cell Technologies Ltd., Director at BioMarker Strategies LLC (2010-2012) and Intellikine LLC (2007-2012), Director at G1 Therapeutics, Inc. (2014-2023), Principal at Yale-New Haven Hospital, Inc., and Executive Vice President at The Leukemia & Lymphoma Society, Inc. (2012-2014).
Dr. Velleca's education includes a doctorate from the University of Washington and an undergraduate degree from Yale University.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
G1 THERAPEUTICS, INC.
0.22% | 08-08-2023 | 116 000 ( 0.22% ) | 501 120 $ | 31-03-2024 |
14-02-2024 | 46 522 ( 0.09% ) | 235 867 $ | 31-03-2024 |
Actieve functies van Mark Velleca
Bedrijven | Functie | Begin |
---|---|---|
BLACK DIAMOND THERAPEUTICS, INC. | Chief Executive Officer | 16-09-2023 |
Yale University | Corporate Officer/Principal | - |
Turbine Hálózatelemzo Kutatási Fejlesztési Kft.
Turbine Hálózatelemzo Kutatási Fejlesztési Kft. Packaged SoftwareTechnology Services Part of Turbine Simulated Cell Technologies Ltd., Turbine Hálózatelemzo Kutatási Fejlesztési Kft. The Hungarian company specializes in unlocking therapies with simulated cells™. Turbine computationally simulates tumor cell behavior in patients to understand the complex mechanisms driving the disease. The simulations can reveal the right modality and combination approach to treat even the most resistant cancers. The private company's platform enables the simulation of drug-like effects from compounds that may not exist yet, on cells potentially unavailable for lab-based testing, like those of high unmet need cancer patients. is a Budapest-based company founded in 2013 by Daniel Veres, Szabolcs Nagy, and Kristof Zsolt Szalay. Szabolcs Nagy has been the CEO since 2013. | Chairman | 28-04-2021 |
IMMvention Therapeutix, Inc.
IMMvention Therapeutix, Inc. BiotechnologyHealth Technology IMMvention Therapeutix, Inc. is an American biotechnology company that develops therapies. The company was founded by Jenny Ting and the CEO is Anil K. Goyal. | Director/Board Member | - |
StrideBio, Inc.
StrideBio, Inc. BiotechnologyHealth Technology Stridebio, Inc. focuses on creating and developing novel adeno-associated viral vector technologies. The company was founded by Aravind Asokan, Mavis Agbandje-McKenna and Patrick Ritschel and is headquartered in Durham, NC. | Chief Executive Officer | 04-02-2022 |
Eerdere bekende functies van Mark Velleca
Bedrijven | Functie | Einde |
---|---|---|
G1 THERAPEUTICS, INC. | Chief Executive Officer | 01-01-2021 |
The Leukemia & Lymphoma Society, Inc.
The Leukemia & Lymphoma Society, Inc. Miscellaneous Commercial ServicesCommercial Services The Leukemia & Lymphoma Society, Inc. operates as the world's largest voluntary health organization dedicated to funding blood cancer research, education and patient services. The firm provides treatment for , lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. It identifies and funds the most promising blood cancer research projects and forges partnerships with academic institutions, biotechnology and pharmaceutical companies to accelerate the development of new therapies. The company is headquartered in Rye Brook, NY. | Corporate Officer/Principal | 01-04-2014 |
BioMarker Strategies LLC
BioMarker Strategies LLC Pharmaceuticals: GenericHealth Technology BioMarker Strategies LLC develops medicines for cancer. It provides cancer diagnostics system for predictive tests to guide targeted drug development and treatment selection for patients with solid tumor malignancies. The company was founded by Scott Allocco, Kathleen Murphy and Douglas P. Clark in May 2006 and is headquartered in Rockville, MD. | Director/Board Member | 01-01-2012 |
Intellikine LLC
Intellikine LLC Pharmaceuticals: MajorHealth Technology Intellikine LLC develops and manufactures small molecule drugs for the treatment of cancer. The company focused on the development of potent, selective small molecule inhibitors of the PI3K/Akt/mTOR pathway for the treatment of cancer, inflammation and autoimmune disorders. Intellikine was founded on May 2nd, 2007 and is headquartered in La Jolla, CA. | Director/Board Member | 01-01-2012 |
░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
Opleiding van Mark Velleca
University of Washington | Doctorate Degree |
Yale University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
G1 THERAPEUTICS, INC. | Health Technology |
BLACK DIAMOND THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 9 |
---|---|
BioMarker Strategies LLC
BioMarker Strategies LLC Pharmaceuticals: GenericHealth Technology BioMarker Strategies LLC develops medicines for cancer. It provides cancer diagnostics system for predictive tests to guide targeted drug development and treatment selection for patients with solid tumor malignancies. The company was founded by Scott Allocco, Kathleen Murphy and Douglas P. Clark in May 2006 and is headquartered in Rockville, MD. | Health Technology |
Gilead Connecticut, Inc.
Gilead Connecticut, Inc. Pharmaceuticals: MajorHealth Technology Gilead Connecticut, Inc. manufactures pharmaceuticals and biotechnology chemicals. The firm develops a pipeline of small molecule therapeutics for multiple oncology and immunology-based indications. It focuses on the development of novel kinase inhibitors for the treatment of cancer, autoimmune, and inflammatory diseases. The company was founded in 2000 and is headquartered in Foster City, CA. | Health Technology |
Yale-New Haven Hospital, Inc.
Yale-New Haven Hospital, Inc. Hospital/Nursing ManagementHealth Services Yale-New Haven Hospital, Inc. provides health care services and medical courses. The firm’s clinical programs and services include advanced vascular imaging services, allergy and immunology, ambulatory services, bariatric surgery program, cardiac rehabilitation, dental services, dermatology services, diabetes and endocrinology, ear, nose & throat (otolaryngology), electrophysiology and cardiac arrhythmia service and interventional cardiology. The company was founded in 1826 and is headquartered in New Haven, CT. | Health Services |
The Leukemia & Lymphoma Society, Inc.
The Leukemia & Lymphoma Society, Inc. Miscellaneous Commercial ServicesCommercial Services The Leukemia & Lymphoma Society, Inc. operates as the world's largest voluntary health organization dedicated to funding blood cancer research, education and patient services. The firm provides treatment for , lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. It identifies and funds the most promising blood cancer research projects and forges partnerships with academic institutions, biotechnology and pharmaceutical companies to accelerate the development of new therapies. The company is headquartered in Rye Brook, NY. | Commercial Services |
Intellikine LLC
Intellikine LLC Pharmaceuticals: MajorHealth Technology Intellikine LLC develops and manufactures small molecule drugs for the treatment of cancer. The company focused on the development of potent, selective small molecule inhibitors of the PI3K/Akt/mTOR pathway for the treatment of cancer, inflammation and autoimmune disorders. Intellikine was founded on May 2nd, 2007 and is headquartered in La Jolla, CA. | Health Technology |
StrideBio, Inc.
StrideBio, Inc. BiotechnologyHealth Technology Stridebio, Inc. focuses on creating and developing novel adeno-associated viral vector technologies. The company was founded by Aravind Asokan, Mavis Agbandje-McKenna and Patrick Ritschel and is headquartered in Durham, NC. | Health Technology |
Turbine Hálózatelemzo Kutatási Fejlesztési Kft.
Turbine Hálózatelemzo Kutatási Fejlesztési Kft. Packaged SoftwareTechnology Services Part of Turbine Simulated Cell Technologies Ltd., Turbine Hálózatelemzo Kutatási Fejlesztési Kft. The Hungarian company specializes in unlocking therapies with simulated cells™. Turbine computationally simulates tumor cell behavior in patients to understand the complex mechanisms driving the disease. The simulations can reveal the right modality and combination approach to treat even the most resistant cancers. The private company's platform enables the simulation of drug-like effects from compounds that may not exist yet, on cells potentially unavailable for lab-based testing, like those of high unmet need cancer patients. is a Budapest-based company founded in 2013 by Daniel Veres, Szabolcs Nagy, and Kristof Zsolt Szalay. Szabolcs Nagy has been the CEO since 2013. | Technology Services |
IMMvention Therapeutix, Inc.
IMMvention Therapeutix, Inc. BiotechnologyHealth Technology IMMvention Therapeutix, Inc. is an American biotechnology company that develops therapies. The company was founded by Jenny Ting and the CEO is Anil K. Goyal. | Health Technology |
Turbine Simulated Cell Technologies Ltd.
Turbine Simulated Cell Technologies Ltd. Information Technology ServicesTechnology Services Turbine Simulated Cell Technologies Ltd. is a British company that leverages AI technology to understand oncology patients with simulated cells. The company is based in London, UK. and has subsidiaries in Hungary. The company was founded in 2019 by Szabolcs Nagy, Ivan Fekete, Daniel Veres, Kristof Zsolt Szalay. Szabolcs Nagy has been the CEO since 2019. | Technology Services |